A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer

Gynecologic Oncology

Volumn 137, Issue 3, 2015, Pages 490-496

  Minion, Lindsey E ^a   Bai, Jiaru ^b   Monk, Bradley J ^a   Robin Keller, L ^b   Ramez, Eskander N ^c   Forde, Gareth K ^b,c   Chan, John K ^d   Tewari, Krishnansu S ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PALO ALTO MEDICAL FOUNDATION   (United States)

Author keywords

Antiangiogenesis therapy; Bevacizumab; Cervical cancer; Cost effectiveness; Markov model

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; ANGIOGENESIS INHIBITOR; BIOSIMILAR AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH STATUS; HIDDEN MARKOV MODEL; HUMAN; INTERNAL VALIDITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT RESPONSE; UTERINE CERVIX CANCER; CANCER STAGING; COST BENEFIT ANALYSIS; ECONOMICS; MORTALITY; PATHOLOGY; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; UTERINE CERVICAL NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOSIMILAR PHARMACEUTICALS; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG COSTS; FEMALE; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UTERINE CERVICAL NEOPLASMS;

EID: 84930042964     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.02.027     Document Type: Article

References (40)

1. B.J. Monk, M.W. Sill, D.S. McMeekin, and D.E. Cohn Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study J. Clin. Oncol. 27 2009 4649 4655
2. B.J. Monk, M.W. Sill, and R.A. Burger Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J. Clin. Oncol. 27 2009 1069 1074
3. K.S. Tewari, M.W. Sill, and H.J. Long III Improved survival with bevacizumab in advanced cervical cancer N. Engl. J. Med. 370 2014 734 743
4. R.T. Penson, H.Q. Huang, and L.B. Wenzel Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Gropu protocol 240) Lancet Oncol 16 2015 301 311
5. FDA News Release FDA Approves Avastin to Treat Patients With Aggressive and Late-stage Cervical Cancer August 14, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm410121.htm
6. K.S. Tewari, M.W. Sill, and R.T. Penson Final protocol-specified overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer Annual Meeting, European Society of Medical Oncology, Madrid, Spain, Late-Breaking Abstract 26 May 29 2014
7. N.T. Phippen, C.A. Leath III, L.J. Havrilesky, and J.C. Barnett Bevacizumab in recurrent, persistent or advanced stage carcinoma of the cervix: is it cost-effective? Gynecol. Oncol. 136 2015 43 47
8. R.H. Shachtman, J.R. Schoenfelder, and C.J. Hogue Conditional rate derivation in the presence of intervening variables using a Markov chain Oper. Res. 30 1982 1070 1081
9. L. Standfleid, T. Comans, and P. Scuffham Markov modeling and discrete event simulation in health care: a systematic comparison Int. J. Technol. Assess. Health Care 30 2014 165 172
10. T. Refaat, M. Choi, and G. Gaber Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer Am. J. Clin. Oncol. 37 2013 480 485
11. A.J. Montero, K. Avancha, and S. Glück A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer Breast Cancer Res. Treat. 132 2012 747 751
12. A. Lloyd, B. Nafees, and J. Narewska Health state utilities for metastatic breast cancer Br. J. Cancer 95 2006 683 690
13. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 2004 2335 2342
14. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J. Clin. Oncol. 25 2007 1539 1544
15. O. Ruiz-Millo, A. Albert-Mari, and A. Sendra-Garcia Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer J. Oncol. Pharm. Pract. 20 2014 341 350
16. T. Shiroiwa, T. Fukuda, and K. Tsutani Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan Clin. Ther. 29 2007 2256 2267
17. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer N. Engl. J. Med. 355 2006 (2542-40)
18. C.R. Chien, and Y.C. Shih Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC) Clinicoecon. Outcomes Res. 4 2012 201 208
19. B. Escudier, A. Pluzanska, and P. Koralewski AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial Lancet 370 2007 2103 2111
20. A. Benedict, R.A. Figlin, and P. Sandstrom Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma BJU Int. 108 2011 665 672
21. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N. Engl. J. Med. 357 2007 2666 2676
22. H.S. Friedman, M.D. Prados, and P.Y. Wen Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J. Clin. Oncol. 27 2009 4733 4740
23. T.N. Kreisl, L. Kim, and K. Moore Phase II trial of single agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J. Clin. Oncol. 27 2009 740 745
24. M.R. Gilbert, J.J. Dignam, and T.S. Armstrong A randomized trial of bevacizumab for newly diagnosed glioblastoma N. Engl. J. Med. 370 2014 699 708
25. O.L. Chinot, W. Wick, and W. Mason Bevacizumab plus radiotherapy - temozolomide for newly diagnosed glioblastoma N. Engl. J. Med. 370 2014 709 722
26. CATT Research Group, D.F. Martin, M.G. Maguire, and G.S. Ying Ranibizumab and bevacizumab for neovascular age-related macular degeneration N. Engl. J. Med. 364 2011 1897 1908
27. R.A. Burger, M.F. Brady, and M.A. Bookman Incorporation of bevacizumab in the primary treatment of ovarian cancer. Gynecologic Oncology Group N. Engl. J. Med. 365 2011 2473 2483
28. T.J. Perren, A.M. Swart, and J. Pfisterer ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer N. Engl. J. Med. 365 2011 2484 2496
29. C. Aghajanian, S.V. Blank, and B.A. Goff OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J. Clin. Oncol. 30 2012 2039 2045
30. E. Pujade-Lauraine, F. Hilpert, and B. Weber Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial J. Clin. Oncol. 32 2014 1302 1308
31. D.E. Cohn, K.H. Kim, and K.E. Resnick At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis J. Clin. Oncol. 29 2011 1247 1251
32. J.K. Chan, T.J. Herzog, and L. Hu Bevacizumab in treatment of high-risk ovarian cancer - a cost-effectiveness analysis Oncologist 19 2014 523 527
33. J.J. Patel, M.A. Mendes, and M. Bounthavong Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model J. Eval. Clin. Pract. 18 2012 247 255
34. M. Goodman Market watch: pharma industry strategic performance: 2007-2012E Nat. Rev. Drug Discov. 7 2008 967
35. Roche Finance Report Jan 28, 2013 - Roche Group - Financial Review Available at www.roche.com/fb123.pdf 2012 (Accessed on February 22, 2015)
36. H. Kantarjian, C. Sawyers, and A. Hochhaus Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N. Engl. J. Med. 346 2002 645 652
37. H.C. Ebbers, P.J. van Meer, and E.H. Moors Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab Drug Discov. Today 18 2013 872 879
38. J.M. Beck Reichert Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry MAbs 5 2013 621 623
39. Avastin (Bevacizumab by Roche) https://gmrdata.com/downloadable/download/linkSample/link-id/12/
40. Generics and Biosimilars Initiative, update http://gabioline.net/Biosimilars/General/Biosimilars-of-bevacizumab